Ketorolac (Toradol) for Acute Migraine Treatment
Yes, ketorolac is an effective option for acute migraine treatment in adults, particularly when administered intravenously in the emergency department setting, though it is not specifically highlighted as a first-line agent in the most recent outpatient migraine guidelines.
Guideline-Based Recommendations
The 2025 American College of Physicians guideline for acute episodic migraine in outpatient settings recommends NSAIDs as part of the treatment algorithm but does not specifically mention ketorolac among the named NSAIDs (aspirin, celecoxib, diclofenac, ibuprofen, or naproxen) 1. The guideline emphasizes:
- Start with an NSAID or acetaminophen for initial treatment
- Add a triptan to an NSAID if adequate doses of NSAID alone provide insufficient pain relief
- Begin treatment as early as possible after migraine onset
Emergency Department Context: Where Ketorolac Shines
The 2025 American Headache Society guideline for parenteral migraine treatment in the emergency department provides strong evidence for intravenous ketorolac 2:
- Ketorolac IV is "likely effective" based on class I evidence
- Should be offered (Level B recommendation) to eligible adults presenting to the ED with migraine requiring parenteral therapy
- Effective for both short-term headache relief and sustained pain relief
Comparative Effectiveness
Ketorolac performs well against other migraine treatments:
- Superior to placebo for 2-hour pain relief (72.5% vs 38.3%) and pain freedom (43.1% vs 18.4%) 3
- Non-inferior to sumatriptan nasal spray for acute migraine treatment 3
- More effective than intranasal sumatriptan in one systematic review 4
- Similar efficacy to meperidine at 60 minutes, but less addictive 4
- Comparable to metoclopramide for most outcomes, though metoclopramide may have slight advantage for short-term relief 5
Route of Administration Matters
Intravenous/Intramuscular (Parenteral)
- Most evidence supports IV/IM ketorolac for acute migraine in ED settings 2, 4
- Typical dose: 30-60 mg IV/IM (though current FDA guidance emphasizes lower dosing)
Nasal Spray
- Ketorolac nasal spray 31.5 mg is effective and superior to placebo 3
- Provides sustained 24-hour pain freedom better than sumatriptan nasal spray
Oral
- FDA-approved only as continuation therapy after IV/IM initiation 6
- Total duration (IV/IM + oral) must not exceed 5 days 6
- Oral ketorolac shows acceptable safety profile when used appropriately 7
Critical Safety Considerations and Contraindications
Absolute Contraindications (per FDA label) 6:
- Active or history of peptic ulcer disease or GI bleeding
- Advanced renal impairment or risk of renal failure
- Hemorrhagic stroke risk or cerebrovascular bleeding
- Pregnancy (especially ≥30 weeks gestation) - can cause premature closure of ductus arteriosus
- Labor and delivery
- Aspirin or NSAID hypersensitivity
- Concurrent use with other NSAIDs
High-Risk Populations Requiring Extreme Caution:
- Elderly patients (≥65 years): Require reduced dosing and careful monitoring 6
- Patients on anticoagulation or with bleeding disorders
- Moderate renal impairment
- Cardiovascular disease
Duration Limits Are Non-Negotiable:
- Maximum 5 days total therapy (combined IV/IM and oral) 6
- Risk of serious adverse events increases significantly beyond 5 days 8
- Risk of medication overuse headache with ≥15 days/month use 1
Practical Clinical Algorithm
For Outpatient Migraine:
- First-line: Start with oral NSAIDs (ibuprofen 400-800mg, naproxen 500-1000mg) or aspirin-acetaminophen-caffeine combination 1, 9
- If inadequate response: Add oral triptan to NSAID
- Consider ketorolac nasal spray as alternative NSAID option if patient prefers or other NSAIDs ineffective 3
For Emergency Department Migraine:
- Offer IV ketorolac 30mg (or IM if IV access unavailable) as effective parenteral option 2
- Alternative first-line options: Prochlorperazine IV or metoclopramide IV (both with strong evidence) 2
- Consider combination: Ketorolac + antiemetic for patients with significant nausea
- Provide oral continuation therapy if needed, but limit total duration to ≤5 days 6
Common Pitfalls to Avoid
- Do not use ketorolac as chronic migraine prevention - it's for acute treatment only
- Do not exceed 5-day total duration - serious GI and renal complications increase dramatically
- Do not use in pregnancy, especially third trimester 6
- Do not combine with other NSAIDs - increases toxicity without added benefit
- Screen for GI bleeding risk factors before prescribing (age >65, anticoagulants, corticosteroids, history of ulcers)
- Avoid in patients with cardiovascular disease unless benefits clearly outweigh risks
Adverse Effects Profile
Most common adverse effects 3, 8:
- Nasal burning and dysgeusia (with nasal spray)
- GI upset, nausea
- Injection site pain (with IM)
Serious but rare adverse effects 8:
- GI bleeding/perforation (risk increases with duration >5 days)
- Acute renal failure (usually reversible with discontinuation)
- Platelet inhibition with bleeding complications
- Allergic/hypersensitivity reactions
The safety profile is acceptable when used at appropriate doses for ≤5 days in properly selected patients 7.